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Objectives. The purposes of this study were to examine the
effects of dipyridamole infusion on hemodynamic variables and to
compare these changes with myocardial perfusion.
Background. Dipyridamole stress testing with myocardial per-
fusion imaging is widely used in the assessment of patients with
known or suspected coronary artery disease (CAD). Few studies,
however, have correlated the hemodynamic effects of dipyridamole
using invasive monitoring with perfusion patterns in patients with
chest pain syndromes.
Methods. Hemodynamic measurements were made in the car-
diac catheterization laboratory with a Swan-Ganz thermodilution
catheter before, during and after infusion of dipyridamole
(142 mg/kg body weight per min for 4 min). Technetium-99m
sestamibi was injected 3 min after the completion of the infusion.
Results. There were 20 patients with and 6 without CAD, as
demonstrated by angiography. Compared with baseline values,
dipyridamole resulted in an increase in pulmonary capillary
wedge pressure (54 6 78% vs. 32 6 26%, p 5 NS), cardiac index
(36 6 21% vs. 40 6 18%, p 5 NS) and stroke volume index (16 6
18% vs. 40 6 18%, p 5 NS) and a decrease in systemic vascular
resistance (22 6 13% vs. 24 6 11%, p 5 NS), aortic pressure (2 6
9% vs. 0 6 6%, p 5 NS) and pulmonary vascular resistance (19 6
25% vs. 11 6 32%, p 5 NS) in patients with and without CAD. The
peak effect of dipyridamole on heart rate, systemic vascular
resistance and pulmonary capillary wedge pressure was evident at
3 min after infusion in 70% of patients. Aminophylline, given to 20
patients, improved hemodynamic variables within 2 min. The
single-photon emission computed tomographic sestamibi images
were normal in the 6 patients without and abnormal in the 18
patients with CAD.
Conclusions. Dipyridamole-induced coronary hyperemia pro-
duces mild hemodynamic changes in patients with and without
CAD; these changes are at or near peak effect at 3 min after
infusion and are rapidly reversed by aminophylline.
(J Am Coll Cardiol 1998;31:75–82)
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Dipyridamole myocardial perfusion scintigraphy is useful in
detecting coronary artery disease (CAD) in patients with
exercise limitations and has been used extensively in risk
assessment in patients with stable angina after acute myocar-
dial infarction and before major noncardiac surgery (1–11).
Intravenous dipyridamole causes coronary vasodilation by
stimulation of adenosine A2 receptors due to inhibition of
cellular reuptake of endogenous adenosine (12,13). Because of
the indirect action of dipyridamole, the maximal coronary
vasodilation occurs some time after the completion of intrave-
nous infusion. In addition, the vasodilatory effect of dipyrida-
mole persists longer than that of adenosine because of the long
biologic half-life of dipyridamole (;30 to 45 min). Intravenous
adenosine, in contrast, is a direct coronary vasodilator with a
very short half-life (14,15).
We have previously evaluated the hemodynamic responses
during adenosine infusion in patients with and without CAD
and observed transient and at times marked changes in left
ventricular filling pressure, cardiac output and systemic vascu-
lar resistance (16). It is unclear whether these effects are
unique to adenosine or can also occur with dipyridamole. The
purposes of this study were, therefore, to examine the central
hemodynamic effects of dipyridamole infusion and to compare
these changes with myocardial perfusion using single-photon
emission computed tomographic (SPECT) imaging with
technetium-99m (Tc-99m) sestamibi in patients undergoing
coronary angiography for chest pain syndromes.
Methods
Patient group. This study involved patients undergoing
cardiac catheterization and coronary angiography for the eval-
uation of chest pain syndromes (including those who were
found not to have significant CAD on angiography). Each
patient signed a consent form approved by the Institutional
Review Board. The investigational studies were performed
20 min after completion of diagnostic cardiac catheterization.
There were no complications related to the study. Patients with
unstable angina, acute myocardial infarction, nonischemic
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cardiomyopathy or chronic obstructive pulmonary disease re-
quiring methylxanthine or beta-agonist therapy were excluded.
Of the 31 patients enrolled in the study, five were subsequently
excluded and did not receive dipyridamole (two with severe
left main coronary artery disease and three with dilated,
nonischemic cardiomyopathies). The remaining 26 patients
completed the hemodynamic and imaging studies. The patients
do not represent consecutive patients undergoing cardiac
catheterization; the selection was based on willingness of the
patients to participate in the study, time constraints and
logistical considerations in coordinating the schedule of the
catheterization and nuclear laboratories and personnel. All
patients had stable symptoms and none had unstable angina or
acute myocardial infarction.
Study design. Antianginal medications were withheld on
the morning of the procedure. Arterial and venous access was
obtained using the modified Seldinger technique. Standard
right heart catheterization was performed using a Swan-Ganz
thermodilution catheter. The following measurements were
obtained: pulmonary artery pressure (phasic and mean), pul-
monary capillary wedge pressure (phasic and mean) and
thermodilution cardiac output using the average of three deter-
minations. The total systemic vascular resistance (dyneszszcm25)
was calculated as (Mean aortic pressure/Cardiac output) 3 80,
and pulmonary vascular resistance (dyneszszcm25) was calcu-
lated as (Mean pulmonary artery pressure 2 Mean pulmonary
capillary wedge pressure)/Cardiac output 3 80. Left ventricu-
lography (right anterior oblique projection) and coronary
angiography using iohexol nonionic contrast agent (Om-
nipaque, Winthrop-Breon) were performed by the Judkins
technique in each patient. After the diagnostic cardiac cathe-
terization, 20 min was allowed for hemodynamic measure-
ments to return to baseline. The patients then received dipyr-
idamole infusion (142 mg/kg body weight per min for 4 min)
(Persantine, E. I. DuPont DeNemours). Hemodynamic mea-
surements were recorded before infusion, during every minute
of infusion and at 3-min intervals after infusion (starting at the
fourth minute of infusion) and after aminophylline (100 mg
administered intravenously). The duration of hemodynamic
monitoring was determined by the presence and severity of
side effects and patient convenience.
Three minutes after the completion of the dipyridamole
infusion, 20 to 30 mCi Tc-99m sestamibi (Cardiolite, E. I.
DuPont DeNemours) was injected intravenously. After re-
moval of the venous and arterial introducer sheaths, the
patient was moved to the nuclear cardiology laboratory and
SPECT imaging was obtained (;60 min after sestamibi injec-
tion). The next day, 20 to 30 mCi of Tc-99m sestamibi was
reinjected at rest and SPECT images were obtained 1 h later.
Single-photon emission computed tomographic Tc-99m
sestamibi imaging. Single-photon emission computed tomo-
graphic scan acquisition was performed on a GE 400AT
rotating gamma camera/Starcam computer system (GE Med-
ical Systems). Thirty-two images were obtained over an ante-
rior 180° arc according to methods previously used in our
laboratory (17). The sestamibi images were interpreted by two
experienced observers who had no previous knowledge of the
cardiac catheterization results. The perfusion pattern was
interpreted as normal or showing a fixed or reversible abnor-
mality in the vascular territories of each of the three main
vessels.
Statistical analysis. The results were expressed as the
mean value 6 SD. The Wilcoxon signed-rank test was used to
compare the mean responses of the same group before and
after dipyridamole administration, and Friedman one-way
analysis of variance was used to analyze group differences.
When the assumption of homogeneity of variance among
groups was violated, the Kruskal-Wallis test was used. Tests of
differences were done by the t test with the Bonferroni
correction for multiple tests, or the chi-square test with Yates’
correction or the Fisher exact test. Statistical differences with a
value ,0.05 were considered significant.
Results
There were 19 men and 7 women (age 57 6 12 years).
There were six patients without and 20 patients with CAD,
defined as $50% lumen diameter stenosis in one or more
vessels measured by quantitative coronary arteriography (using
the Analytic Development Associate Corporation edge-
detection method); nine patients had one-vessel disease; seven
patients had two-vessel disease; and four patients had three-
vessel disease. Collateral channels were visible on the angio-
gram in eight patients (40%). The patients without CAD were
younger than the patients with CAD. More patients with than
without CAD had diabetes mellitus or were taking antianginal
medications. The mean left ventricular ejection fraction was
normal in patients with and without CAD (Table 1).
Hemodynamic changes during dipyridamole infusion (Ta-
bles 2 and 3). The baseline hemodynamic measurements
(before dipyridamole infusion) in patients with and without
CAD are presented in Table 2. The patients with CAD had a
slightly lower stroke volume index and higher pulmonary
vascular resistance than patients without CAD (p , 0.05).
The hemodynamic changes after dipyridamole infusion in
patients with and without disease are shown in Table 3. There
was no significant change in aortic pressure owing to direction-
ally opposite changes in cardiac output and systemic vascular
resistance. The increase in heart rate was less in patients with
than in those without CAD. There were increases in pulmo-
nary capillary wedge pressure and pulmonary artery pressure
(more marked in patients with than in those without CAD, p ,
0.05) and a decrease in pulmonary vascular resistance. The
increase in cardiac index was similar in patients with and
without CAD. The increase in cardiac index was due to
Abbreviations and Acronyms
CAD 5 coronary artery disease
SPECT 5 single-photon emission computed tomographic
Tc-99m 5 technetium-99m
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increases in heart rate and stroke volume. The decrease in
systemic vascular resistance was greater than the decrease in
pulmonary vascular resistances (p , 0.005). The change in
pulmonary capillary wedge pressure was 40 6 21% in five
patients who had dyspnea and 60 6 70% in those without it
(p 5 NS). The increase in wedge pressure was 81 6 84% in 14
patients with normal baseline pressure (,12 mm Hg) and 31 6
17% in patients with elevated pressure (p , 0.05). The change
in wedge pressure was 98 6 99% in seven patients with an
anteroseptal perfusion abnormality compared with 43 6 44%
in 19 patients with no anteroseptal defect (p 5 NS).
Timing of hemodynamic responses. The time to peak effect
of various hemodynamic responses is shown in Figure 1. In
most patients (70%), the peak effect was evident at 3 min after
infusion; the change between 3 and 7 min after infusion was
minimal (Table 3). In eight patients with CAD and one patient
without CAD, prominent V waves (.30 mm Hg) were evident
in pulmonary capillary wedge pressure tracings after dipyrida-
mole infusion (Fig. 2). Of the patients with CAD, three had
one-vessel disease, three had two-vessel disease and two had
three-vessel disease. Collateral channels were present in five of
the eight patients with CAD and prominent V waves compared
with three of 12 patients with CAD but no large V waves (p 5
NS). All five patients who developed ST segment changes
during dipyridamole infusion had CAD and also developed
prominent V waves. Collateral channels were present in four
of the five patients with ST segment depression. No patients
without CAD had ST segment depression.
In patients with CAD, the changes in pulmonary artery
pressure, pulmonary capillary wedge pressure, cardiac output,
aortic pressure and systemic vascular resistance were compa-
rable between patients with collateral channels (n 5 8) and
those with no collateral channels (n 5 12).
Effects of aminophylline. Aminophylline was given to 13
patients with CAD (65%) and one patient without CAD (p 5
NS) for persistent symptoms (Table 4). Chest pain was the
most common side effect occurring in patients with and
without CAD. Heart rate, mean pulmonary artery pressure
and pulmonary capillary wedge pressure rapidly decreased
after aminophylline administration. These variables returned
to baseline by 5 min in most patients (Table 3). Resolution of
symptoms occurred within 2 min of administration.
Single-photon emission computed tomographic Tc-99m
sestamibi imaging. All six patients without CAD had normal
images (specificity 100%), whereas 18 of the 20 patients with
disease had perfusion abnormalities (sensitivity 90%). In 16
patients, the perfusion defects were either partial or com-
pletely reversible. In the remaining two patients, only fixed
defects were seen. Perfusion defects were seen in seven of nine
patients with one-vessel disease, seven of seven patients with
two-vessel disease and four of four patients with three-vessel
disease. Reversible perfusion defects were seen in five of five
patients with ST segment depression. In patients with multives-
sel disease, perfusion defects were detected in 16 of 26
stenoses. The stenosis severity was 80 6 18% in those with
defects and 64 6 15% in those without defects as demon-
strated by quantitative angiography (p , 0.01). There was no
relation between the extent of perfusion abnormality, mea-
sured as the number of segments (based on a model of 20
segments per patient) with perfusion abnormalities, and the
peak pulmonary capillary wedge pressure during dipyridamole
infusion (r 5 0.27, p 5 NS) (Fig. 3). The size of the defect was
4.9 6 3.3 segments in the eight patients who developed
prominent V waves and 3.6 6 3.5 segments in those who did
not (p 5 NS).
Discussion
This study showed that the standard dose of intravenous
dipyridamole (142 mg/kg per min for 4 min) caused mild but
significant hemodynamic changes for several minutes after
termination of infusion, which reverted promptly to baseline
Table 1. Pertinent Data in Patients With and Without Coronary
Artery Disease
CAD
(n 5 20)
No CAD
(n 5 6) p Value
Age (yr) 60 6 11 48 6 12 0.04
Male/female 13/7 6/0 NS
Typical angina 16 (80%) 2 (33%) NS
Q wave myocardial infarction 10 (50%) 0 (0%) NS
Hypertension 11 (55%) 4 (67%) NS
Diabetes mellitus 5 (25%) 0 (0%) NS
Family history of CAD 11 (55%) 3 (50%) NS
Nitrates 9 (45%) 1 (17%) NS
Beta-blockers 8 (40%) 2 (33%) NS
Calcium channel antagonists 13 (6.5%) 0 (0%) 0.02
Left ventricular ejection fraction 60 6 9 67 6 3 NS
Coronary anatomy
One-vessel disease 9 (45%)
Two-vessel disease 7 (35%)
Three-vessel disease 4 (20%)
Visible collateral vessels 8 (40%)
Data presented are mean value 6 SD or number (%) of patients. CAD 5
coronary artery disease.
Table 2. Baseline Hemodynamic Values in Patients With and
Without Coronary Artery Disease
CAD
(n 5 20)
No CAD
(n 5 6)
Total
Group
(n 5 26)
Heart rate (beats/min) 76 6 12 69 6 15 75 6 13
Aortic systolic pressure (mm Hg) 154 6 27 139 6 23 151 6 27
Mean PAP (mm Hg) 19 6 4 18 6 4 18 6 4
Mean PCWP (mm Hg) 12 6 4 12 6 3 12 6 3
Cardiac index (liters/min per m2) 3.2 6 0.5 3.4 6 0.8 3.2 6 0.6
Stroke volume index (ml/beat per m2) 42 6 5* 50 6 8 44 6 7
Total SVR (dyneszszcm25) 1,410 6 325 1,137 6 274 1,347 6 331
PVR (dyneszszcm25) 93 6 33* 57 6 32 85 6 35
*p , 0.05 versus no coronary artery disease (CAD). Data presented are
mean value 6 SD. PAP 5 pulmonary artery pressure; PCWP 5 pulmonary
capillary wedge pressure; PVR 5 pulmonary vascular resistance; SVR 5
systemic vascular resistance.
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after aminophylline administration. There were increases in
heart rate, stroke volume and cardiac index and decreases in
systemic and pulmonary vascular resistance in patients with
and without CAD. The pulmonary capillary wedge pressure
increased slightly in patients with and without CAD, and some
patients with CAD developed prominent V waves. Most
patients (90%) with CAD had abnormal SPECT images,
whereas the patients without CAD had normal images.
Hemodynamic changes during dipyridamole infusion.
Many studies have demonstrated that intravenous adenosine
and dipyridamole produce a slight increase in heart rate and a
slight decrease in blood pressure, and thus only a modest
change in rate–pressure product (18–25). The increase in heart
rate may be related to adenosine-induced sympathetic stimu-
lation, or as reflex tachycardia secondary to hypotension
(26–30). The decrease in systemic blood pressure is probably
caused by a direct vasodilatory effect on systemic circulation
through activation of adenosine A2 receptors. The lack of
significant changes in systemic blood pressure in this study may
be related to volume expansion as a result of coronary angiog-
raphy and left ventriculography. In a recent study, Taillefer et
al. (31) reported a greater decrease in systolic blood pressure
with adenosine than with dipyridamole (212 6 11 vs. 25 6
10 mm Hg, p , 0.001).
Few studies in humans have evaluated the effects of aden-
osine and dipyridamole on hemodynamic changes using inva-
sive monitoring in patients with chest pain syndromes. Miller
et al. (23) evaluated the early hemodynamic changes induced
during dipyridamole pharmacologic stress in 10 patients early
after myocardial infarction. They noted a significant increase in
heart rate in association with a decrease in mean arterial
pressure and an increase in mean pulmonary capillary wedge
pressure (from 13 6 5 to 17 6 6 mm Hg) with the development
of large V waves in the pulmonary capillary wedge pressure
tracings in some patients. The development of large transient
V waves was most prominent in patients with a recent anterior
wall myocardial infarction. In addition, they showed a signifi-
cant increase in cardiac index and a decrease in systemic
vascular resistance at peak effect. These hemodynamic re-
sponses were rapidly reversed with intravenous aminophylline.
We previously reported on the hemodynamic responses
during intravenous adenosine administration in patients with
and without CAD (16). In that study, the increase in pulmo-
nary capillary wedge pressure was greater in patients with than
in those without CAD. The patients who had V waves during
adenosine infusion did not develop mitral regurgitation (on
ventriculography) or wall motion abnormality. The other he-
modynamic responses (heart rate, aortic pressure, cardiac
output and vascular resistance) were similar in patients with
and without CAD.
Table 3. Percent Change in Hemodynamic Measurements From Baseline to During and After
Dipyridamole Stress
Hemodynamic
Variable
Time Since Start of Dipyridamole Infusion
1 Min After
Aminophylline
5 Min After
Aminophylline4 Min 7 Min 10 Min 13 Min
HR (%)
CAD 13 6 12* 18 6 15*† 16 6 14*† 14 6 12*† 10 6 13*† 0 6 11†
No CAD 28 6 16* 31 6 12* 25 6 11*† 26 6 16* 14 6 20 NA
SBP (%)
CAD 23 6 8 22 6 9 0 6 12 0 6 13 4 6 10 22 6 10
No CAD 0 6 10 0 6 6 1 6 5 1 6 8 0 6 5 NA
Mean PAP (%)
CAD 13 6 20* 30 6 30*† 34 6 41* 23 6 27* 16 6 34† 24 6 25†
No CAD 9 6 11 20 6 14*† 21 6 21 22 6 19* 22 6 16 NA
Mean PCWP (%)
CAD 17 6 23* 48 6 52*† 54 6 78* 40 6 55* 38 6 63* 2 6 43†
No CAD 22 6 25 23 6 14*† 32 6 26* 21 6 29 21 6 42 NA
CI (%)
CAD 32 6 22* 36 6 21* 34 6 22* 32 6 26* NA NA
No CAD 44 6 19* 40 6 18* 40 6 22* NA
SVI (%)
CAD 16 6 16* 16 6 18* 16 6 16* 17 6 20* NA NA
No CAD 44 6 19* 40 6 18* 40 6 22* NA
Total SVR (%)
CAD 220 6 14* 222 6 13* 222 6 14* 211 6 15† NA NA
No CAD 227 6 10* 224 6 11* 226 6 14* NA
PVR (%)
CAD 213 6 29 219 6 25* 215 6 32 2 6 28 NA NA
No CAD 215 6 25 211 6 32 222 6 43 NA
*p , 0.05 versus baseline value. †p , 0.05 versus previous stage. Data presented are mean value 6 SD. CI 5 cardiac
index; HR 5 heart rate; NA 5 not available; SBP 5 systolic blood pressure; SVI 5 stroke volume index; other
abbreviations as in Table 2.
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A prominent V wave was seen in 8 of 20 patients with CAD
in the present study. All five patients with CAD who developed
ST segment changes during dipyridamole also developed
prominent V waves. Although there may be differences be-
tween our previous patients and those enrolled in the present
study, the changes in hemodynamic data were more marked
during adenosine infusion. These differences between adeno-
sine and dipyridamole may be related to interstitial levels of
adenosine. The study by McLaughlin et al. (28) also showed
only modest changes in pulmonary capillary wedge and pul-
monary artery pressures during dipyridamole infusion. In the
same study, there was also only a modest increase in the
coronary sinus level of adenosine during administration of a
standard dose of dipyridamole. It is unclear whether a larger
Figure 1. Time to peak hemodynamic effects
during dipyridamole stress. Number of pa-
tients (Pts.) with and without coronary artery
disease (CAD) is shown in relation to peak
hemodynamic effect. CO 5 cardiac output;
HR 5 heart rate; PAP 5 pulmonary artery
pressure; PCWP 5 pulmonary capillary
wedge pressure; SVR 5 systemic vascular
resistance. Solid bars 5 CAD; open bars 5
no CAD.
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dose of dipyridamole, as used in many laboratories in Europe,
may have produced a more marked hemodynamic response.
The study by Czernin et al. (32), however, showed no further
increase of myocardial blood flow (measured with nitrogen-13
ammonia and positron emission tomography) with the higher
dose compared with the standard dose. The changes in pulmo-
nary capillary wedge pressure during adenosine or dipyrida-
mole infusion may be related to several factors such as
increased left ventricular stiffness, myocardial ischemia or
increased preload. Ren et al. (33) studied the changes in
myocardial blood volume during adenosine infusion by two-
dimensional echocardiography and showed a greater increase
in patients with than in those without CAD. Nussbacher et al.
(34) suggested that an increase in preload (due to dipyrida-
mole effects on capacitance vessels) may be responsible for the
elevation of filling pressure. The failure of normalization of the
wedge pressure 1 min after aminophylline administration,
which blocks adenosine receptors and thus should have an
instantaneous effect, is not clearly understood. It may support
the preload concept, but further studies are needed to provide
insights into the mechanism of rise in wedge pressure. The
greater increase in pulmonary capillary wedge pressure seen in
our previous study with adenosine compared with dipyrida-
mole may reflect a difference in the patient group, a difference
in the degree of coronary hyperemia, coronary steal or the
degree of change in preload. Previous studies have shown
similar increases in myocardial blood flow with adenosine and
dipyridamole, although Chan et al. (35) observed that maximal
hyperemia is not seen in roughly 25% of patients given
dipyridamole. It should be noted that although an average 50%
increase in wedge pressure was seen in this study, the absolute
wedge pressure increased only from 12 to 18 mm Hg. The
dyspnea, or more appropriately hyperventilation, observed
with dipyridamole or adenosine is most often caused by
stimulation of carotid chemoreceptors (13).
Time to peak hemodynamic response. The time to peak
effect after dipyridamole infusion was at 3 min after infusion in
most patients, consistent with experimental data (36). From
the clinical standpoint, it seems that injection of radiotracer at
3 to 6 min after termination of infusion, as is currently done, is
appropriate. Several studies evaluating the effects of dipyrida-
mole on coronary flow and myocardial metabolism have dem-
onstrated peak dipyridamole effect at comparable times. Wil-
son and White (37) compared the coronary vasodilatory effect
of intravenous dipyridamole with intracoronary papaverine
and meglumine diatrizoate in patients with normal coronary
circulation. Coronary blood flow velocity increased to 4.8 times
the rest value at the completion of the 4-min dipyridamole
infusion (using a similar infusion protocol as in the present
study). This value was 87% of the maximal flow velocity
achieved with papaverine, and was reached at ;6.5 min (range
3.6 to 7.9) after the onset of the infusion. In Wilson and
White’s study, maximal vasodilation persisted for 1.7 to 5.1 min
after achieving maximal coronary blood flow velocity. Feldman
et al. (18) demonstrated that coronary hyperemia, induced by
a 20-mg intravenous bolus of dipyridamole, yielded changes in
regional coronary blood flow and metabolic responses that
were dependent on the status of the arteries supplying the left
Figure 3. The relation between peak pulmonary capillary wedge
pressure (PCWP) and the extent of perfusion abnormality. No statis-
tically significant correlation was noted.
Table 4. Frequency of Side Effects During Dipyridamole Infusion in
Patients With and Without Coronary Artery Disease
CAD
(n 5 20)
No CAD
(n 5 6) p Value
Cardiac
Dyspnea 5 (25%) 0 (0%) NS
Chest pain 16 (80%) 3 (50%) NS
ST segment depression 5 (25%) 0 (0%) NS
Atrioventricular block
(2nd degree, type 1)
1 (5%) 1 (17%) NS
Noncardiac
Headache 5 (25%) 1 (17%) NS
Flushing 4 (20%) 0 (0%) NS
Nausea 0 (0%) 0 (0%) NS
Epigastric discomfort 2 (10%) 0 (0%) NS
Aminophylline treatment 13 (65%) 1 (17%) NS
Data presented are number (%) of patients. CAD 5 coronary artery disease.
Figure 2. Tracings of aortic pressure and pulmonary capillary wedge
pressure before (left) and after (right) dipyridamole (Dipyrid) infu-
sion. There is a marked increase in pulmonary capillary wedge
pressure.
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ventricular region. By 1 min after dipyridamole administration,
the heart rate increased and the systemic blood pressure
decreased significantly compared with baseline values; these
changes persisted .10 min. Total left ventricular myocardial
flow (measured by a flow catheter in the coronary sinus)
increased significantly by 34 s after dipyridamole infusion,
increased to 51% above baseline flow by 1 min and continued
to be elevated 15 min after injection. Seven of 13 patients had
an increase of peak response by 1 min, 4 patients by 5 min and
2 patients by 10 min. Increased coronary blood flow in normal
regions accounted for .75% of the increase in coronary blood
flow. In patients with CAD, flow did not increase in the
myocardium supplied by a stenotic coronary artery.
Marchant et al. (38) compared the hemodynamic effects of
intracoronary versus systemic dipyridamole administration on
coronary blood flow. They suggested that coronary hyperemia
may be due to both direct coronary vasodilation and an
increased double rate–pressure product. Intracoronary dipyr-
idamole achieved a peak level of coronary sinus flow (increase
of 73% from baseline) by 1 min, with minimal hemodynamic
changes. In contrast, intravenous dipyridamole augmented
coronary sinus flow by an additional 88%, with the peak effect
occurring 5 min after administration.
Study limitations. One potential limitation of the study is
the small sample size, especially the group without CAD. We
also excluded patients with more severe disease or severe left
ventricular dysfunction. Some studies have combined exercise
(isometric or dynamic) with dipyridamole to maximize coro-
nary hyperemia and increase the double product. Because this
study was performed in the cardiac catheterization laboratory,
the effect of exercise was not studied. However, Czernin et al.
(32) have shown that the combination of isometric exercise
with dipyridamole may result in a decrease rather than a
further increase in coronary blood flow compared with dipyr-
idamole alone.
The effects of cardiac medications, contrast material and
volume loading on hemodynamic responses should also be
considered. Although in this study, we tried to limit the
amount of contrast material and allowed 20 min after cathe-
terization before the start of the dipyridamole infusion.
Conclusions. Dipyridamole infusion is associated with mild
hemodynamic changes in patients with and without CAD.
Most changes are near peak effect at 7 min from the start of the
infusion. These hemodynamic abnormalities are reversed by
aminophylline and are less prominent than those observed with
adenosine. Thus, in dipyridamole perfusion imaging, the ra-
diotracer may be injected at 7 to 10 min after the start of the
infusion. The prolonged hemodynamic response may poten-
tially be of benefit to enhance extraction of technetium-labeled
tracers.
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